Antiandrogens benign prostatic hyperplasia

S. repens (American dwarf palm tree, cabbage palm, sabal, saw palmetto) has mainly been used to treat benign prostatic hyperplasia. In placebo-controlled and comparative studies its efficacy in benign prostatic hyperplasia and lower urinary tract symptoms has been demonstrated (5). Numerous mechanisms of action have been proposed, including an antiandrogenic action, an anti-inflammatory effect, and an antiproliferative influence through inhibition of growth factors. 

Zanosar streptozodn. zanoterone [inn, usan] (Win 49596) is a steroid, an ANTIANDROGEN, potentially of use in the treatment of benign prostatic hyperplasia and as an ANTICANCER agent for prostate cancer. 

K., Parlow, A.F., Miller, D.D. and Dalton, J.T. (2004) Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5a-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats new approach for benign prostate hyperplasia. Endocrinology, 145, 5420-5428. 

C. 5a-Reductase Inhibitors Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5a-reductase some tissues, most notably prostate cells and heur follicles, depend upon DHT rather than testosterone for androgenic stimulation. This enzyme is inhibited by finasteride, a drug used to treat benign prostatic hyperplasia and, at a lower dose, to prevent hair loss in men. Because the drug does not interfere with the action of testosterone, it is less likely than other antiandrogens to cause impotence, infertility, and loss of libido. 

One final area where steroids are used is as antiandrogens in the treatment of benign prostatic hyperplasia, prostate cancer and male hypersexuality. Dutasteride and finasteride (Fig. 20.34) are specific inhibitors of 5a-reductase, which is involved in the metabolism of testosterone. These two compounds are indicated for the treatment of benign prostatic hyperplasia, with finasteride also being indicated for male-pattern baldness. 

---